Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT05277337
NCT05277337CompletedPhase 4

A Phase IV, Randomized, Interventional, Study to Assess Subject Treatment Session Perception and Investigator Treatment Experience of Alluzience and Vacuum-Dried Botulinum Neurotoxin Type A for Aesthetic Use

Galderma R&D8 sites in 2 countries150 target enrollmentStarted: February 4, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
150
Locations
8
Primary Endpoint
Time Needed to Prepare Alluzience and Powder BoNT A
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is a Phase IV, open-label, randomized, interventional, two-armed, multi-centre study to investigate subject treatment perception and Investigator treatment experience when using Alluzience or vacuum-dried botulinum neurotoxin type A (powder BoNT-A) for treatment of glabellar lines (GL).

Detailed Description

This is a Phase IV, open-label, randomized, interventional, two-armed, multi-centre study to investigate subject treatment perception and Investigator treatment experience when using Alluzience or vacuum-dried botulinum neurotoxin type A (powder BoNT-A) for treatment of glabellar lines (GL).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Female 18 to < 65 years of age.
  • •Moderate to severe GL at maximum frown as assessed by the Investigator.
  • •Female of non-childbearing potential (i.e., postmenopausal [absence of menstrual bleeding for 1 year prior to screening, without any other medical reason], or has undergone hysterectomy or bilateral oophorectomy). OR Female of childbearing potential with a negative urine pregnancy test at screening and baseline, and agrees to use a highly effective and approved contraceptive method for the duration of the study.
  • •Time and ability to complete the study and comply with instructions.
  • •Understands the study requirements and signed the informed consent form (ICF).
  • •Subjects who have planned to undergo aesthetic facial treatment with powder toxin at the study site.
  • •Previous use of any approved botulinum toxin in facial areas.

Exclusion Criteria

  • •Previous use of any botulinum toxin in facial area within 6 months prior to study treatment.
  • •Female who is pregnant, breast feeding, or intends to conceive a child during the study.
  • •Known allergy or hypersensitivity to any component of the study product or any botulinum toxin serotype.
  • •Any known contraindication such as subject with bleeding disorder or subject currently using anticoagulants.
  • •Previous use of any hyaluronic acid soft tissue augmentation therapy in the treated area within 3 months before baseline.
  • •Previous soft tissue augmentation with any permanent (non-biodegradable such as silicone, polyacrylamide, etc) or semi-permanent (i.e., calcium hydroxylapatite, poly-L-Lactic acid or polymethyl-methacrylate) product; lifting threads, or autologous fat in the treatment area.
  • •Subject has any prior or current psychiatric illness (e.g. Psychosis, depression, anxiety), alcohol or drug abuse, or is taking antidepressant, anxiolytic, or antipsychotic medication that, in the Investigator's opinion, could affect the subject's safety and/or participation in the study.
  • •Other concurrent medical conditions, therapy, or other condition that, in the Investigator's opinion, would interfere with the evaluation of the study medication, safety or efficacy, and/or put the subject at risk if he/she participates in the study.
  • •Participation in an investigational device or drug study within 30 days prior to study treatment or plans to enroll in any other investigational study during participation in this study.
  • •Study site personnel, close relatives of the study site personnel (e.g. parents, children, siblings, or spouse), employees or close relatives of employees at the Sponsor company.

Arms & Interventions

Group 1 (Alluzience)

Experimental

Single treatment at the baseline visit with Alluzience. Glabellar lines will be treated with 10 U/0.05 mL per injection point. In total 50 s.U in 0.25 mL for 5 injection points.

Intervention: Alluzience (Biological)

Group 2 (powder BoNT-A: BOTOX/Vistabel)

Active Comparator

Single treatment at the baseline visit with powder BoNT-A (BOTOX/Vistabel). Glabellar lines will be treated with 4 U/0.1 mL per injection point. In total 20 U in 0.5 mL for 5 injection points.

Intervention: powder BoNT-A (BOTOX/Vistabel) (Biological)

Outcomes

Primary Outcomes

Time Needed to Prepare Alluzience and Powder BoNT A

Time Frame: Baseline (Day 0)

Time to prepare Alluzience and powder Bont A according to protocol was reported.

Secondary Outcomes

  • Investigator Treatment Session Questionnaire(Baseline (Day 0))
  • Percentage of Participants Injected With Alluzience for Whom Investigator Did Not Face Technical Issue/Problems When Using a Ready-to-use Product as Compared to a Product to be Reconstituted(Baseline (Day 0))
  • Percentage of Participants Injected With Powder Bont-A for Whom Investigator Experienced Issues While Reconstitution(Baseline (Day 0))

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (8)

Loading locations...

Similar Trials

Completed
Phase 4
A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)Rhinitis, Allergic, Perennial and SeasonalRhinitis, Allergic
NCT02424539GlaxoSmithKline358
Completed
Phase 4
Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).Metastatic Colorectal Cancer
NCT03564938Bayer100
Completed
Phase 4
Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese AdultsHospital Acquired PneumoniaIntra-abdominal InfectionAcute PyelonephritisBacteremiaVentilator-associated PneumoniaUrinary Tract Infection
NCT04882085Pfizer60
Completed
Phase 4
Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During RelapseMultiple Sclerosis
NCT00753792Germans Trias i Pujol Hospital49
Unknown
Phase 4
Clinical Study of Artz in the Treatment of Knee OsteoarthritisKnee Osteoarthritis
NCT02826031Kunming Baker Norton Pharmaceutical Sales Co., Ltd.300